4FMFES-PET Imaging of ER+ Advanced Breast Cancers

Estrogen Receptor (ER) is a crucial prognostic factor and treatment target in breast cancer patients. Knowledge of its status greatly influences the choice of the optimal course of treatment. Pathological evaluations of primary tumor, axillary nodes, and metastases are the only confirmatory approach to ER status determination and are limited to known and accessible sites. However, it is known that many advanced breast cancer patients harbor diseases presenting inter-tumor or temporal ER heterogeneity, as ER expression can vary between tumor foci and can evolve during treatment and at time of r

Trial Details

NCT ID
NCT04824014
Phase
PHASE2
Sponsor
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Status
RECRUITING
Cancer Type
Breast Cancer
Locations (sample)
  • Sherbrooke, Quebec, Canada

Key Eligibility Criteria

  • Advanced breast cancer patients, i.e. stage 3 or 4 diseases.
  • Aged 18 or older at the time of breast cancer diagnosis.
  • Histopathologic review confirming diagnosis of ER positive breast cancer.
  • Male patients, although rare, can participate.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →